Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606034 · ClinicalTrials.gov registry record · Phase 4
U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod
A Phase 4 study, sponsored by Mountain Diabetes and Endocrine Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT00606034 is a Phase 4 study that has completed, run by Mountain Diabetes and Endocrine Center. The registered enrollment target is 21 participants.
The verdict
NCT00606034, a Phase 4 study, has completed, sponsored by Mountain Diabetes and Endocrine Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
Patients with Type 2 diabetes and severe insulin resistance with very large insulin requirements who have failed all previous insulin regimens using non-concentrated forms of insulin (U100 insulin formulations) will receive 5X concentrated insulin (U500 regular insulin)infused via insulin pump.
Interventions
- DRUG U-500 Insulin delivered by Omnipod (disposable insulin pump)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606034
The ClinicalTrials.gov registry entry for NCT00606034 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mountain Diabetes and Endocrine Center, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which U-500 Insulin delivered by Omnipod (disposable insulin pump) is the first listed.
NCT00606034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606034 about?
NCT00606034 is a clinical study titled "U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod". Patients with Type 2 diabetes and severe insulin resistance with very large insulin requirements who have failed all previous insulin regimens using non-concentrated forms of insulin (U100 insulin formulations) will receive 5X concentrated insulin (U500 regular insulin)infused via insulin pump.
What is the current status of trial NCT00606034?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2007-12. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00606034?
The interventions under investigation include: U-500 Insulin delivered by Omnipod (disposable insulin pump) (DRUG).
Who is sponsoring clinical trial NCT00606034?
This trial is sponsored by Mountain Diabetes and Endocrine Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.